Medindia

X

Good Faecal Bacteria Capsule can Treat C Difficile Infection

by Bidita Debnath on  October 7, 2015 at 8:28 PM Research News   - G J E 4
It sure will sound really yuck to some, but researchers have shown that capsules containing a frozen suspension of fecal material harvested from healthy unrelated donors have been found to effectively treat C difficile infection and other bowel conditions.
 Good Faecal Bacteria Capsule can Treat C Difficile Infection
Good Faecal Bacteria Capsule can Treat C Difficile Infection
Advertisement

In clinical trials, the capsules were well tolerated and effectively resolved diarrhea in 90 percent of patients with difficult-to-treat C. difficile infection. C. difficile infection is a type of bacterial infection that causes severe diarrhea, intestinal inflammation and cell death.

Advertisement
According to professor Antonio Gasbarrini from the Gemelli University Hospital in Rome, Italy, an oral formulation that simplifies fecal microbiota transplantation (FMT) is a major step forward.

"FMT is an excellent treatment for C. difficile infection, but traditional methods are time-consuming and technically challenging," he said. "Advances in the preparation and delivery of FMT will lead to its wider acceptance as a safe and effective treatment for C. difficile infection that could supersede antibiotics," Gasbarrini noted.

The consequences of recurrences of C. difficile infection can be severe, resulting in life-threatening illness and frequent hospitalizations. FMT from a healthy donor to an individual with C. difficile infection can restore the healthy gut microbiota and resolve symptoms.

FMT has traditionally been performed using a liquid suspension of feces from a related donor, which is transplanted into the body using a nasogastric tube, endoscopy, enema or colonoscopy. A recent systematic review of the literature concluded that FMT was both effective and safe for the treatment of recurrent C. difficile infection.

"We believe that FMT is an excellent therapeutic option for patients who have failed to respond to antibiotic treatments or who have severe or multiple recurrences," Gasbarrini pointed out.

Professor Gasbarrini is scheduled to present the findings research at the 23rd United European Gastroenterology Week in Barcelona, Spain, later this month.

Source: IANS
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All